FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity

The FDA granted approval to orforglipron (Foundayo), Eli Lilly's once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults with obesity or those who are overweight with at least 1 weight-related comorbidity. It is the only GLP-1 pill that can be taken at any time of day without restrictions on food or water intake.¹

Orforglipron is indicated for use alongside a reduced-calorie diet and increased physical activity to help individuals lose excess body weight and maintain weight reduction long term. The approval marks the continued evolution of the obesity pharmacotherapy landscape, following Novo Nordisk’s oral semaglutide (Wegovy pill), which received FDA approval in December 2025.

The approval was supported by data from the ATTAIN phase 3 clinical development program, which enrolled more than 4500 individuals with obesity or those who are overweight across 2 global registration trials. This 72-week, randomized, double-blind, placebo-controlled study showed that participants taking the highest dose of orforglipron who remained on treatment lost a mean of 27.3 lb (12.4%) compared with 2.2 lb (0.9%) with placebo. Across all treated participants regardless of adherence, mean weight loss was 25 lb (11.1%) vs 5.3 lb (2.1%) with placebo.

Treatment with orforglipron was also associated with reductions in multiple cardiometabolic risk markers, including waist circumference, non–high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure across all doses. These findings are notable given the high cardiovascular burden often accompanying obesity.

A key clinical distinction for orforglipron is its dosing flexibility. Unlike the semaglutide pill, which as an oral peptide must be taken in the morning at least 30 minutes before any food or drinks other than water, orforglipron carries no such requirements.² Additionally, as a small molecule, orforglipron is easier to manufacture than oral semaglutide, which could prove influential in the competition for the oral obesity market.

While Forforglipron's approval marks a significant expansion of oral options for obesity treatment, clinicians and company leadership alike have acknowledged that the pill does not match the efficacy of injectable GLP-1 agents. Eli Lilly CEO Dave Ricks conceded that Zepbound is more effective, but argued that pills still have a meaningful place, noting that patients who have succeeded with injectable therapy may want to transition to something less invasive that does not require refrigerated transport or a weekly injection schedule.² He told CNBC that it is “an option that’s not more effective...but it’s more accessible, it’s easier to fit into your daily routine.” The injectable GLP-1 drugs have produced weight loss exceeding 20% in trials, compared with the 12% average seen with orforglipron at its highest dose over 72 weeks.

Orforglipron will be available via LillyDirect with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through US retail pharmacies and telehealth providers. Eligible patients with commercial insurance may pay as little as $25 per month with a savings card, while self-pay patients can access the drug starting at $149 per month for the lowest dose. Eligible Medicare Part D patients may access the medication for $50 per month beginning as soon as July 1, 2026.¹

Orforglipron carries a boxed warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), and should not be used in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2. The most common adverse effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair loss. Concomitant use with other GLP-1 receptor agonists is not recommended.

References

1. Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. News release. PR Newswire. April 1, 2026. Accessed April 1, 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html

2. Mack J. Eli Lilly GLP-1 pill Foundayo approved for obesity. CNBC. April 1, 2026. Accessed April 1, 2026. https://www.cnbc.com/2026/04/01/eli-lilly-glp-1-pill-foundayo-approved-for-obesity.html